
FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv Plus Pembrolizumab for Urothelial Carcinoma
Enfortumab vedotin-ejfv (Padcev, Astellas Pharma and Seagen Inc) with pembrolizumab (Keytruda, Merck) approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.